Search Medical Condition
Please enter condition
Please choose location

Jongno-gu, Korea, Republic of Clinical Trials

A listing of Jongno-gu, Korea, Republic of clinical trials actively recruiting patients volunteers.

RESULTS

Found (421) clinical trials

A Double-masked Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders

MEDI-551 is a genetically engineered humanized monoclonal antibody that binds to the B cell specific surface antigen CD19 resulting in the depletion of B cells. CD19 positive (CD19+) B-lineage plasmablasts are responsible for the production of autoantibodies against the AQP4 channel protein. The main objective of this study is to ...

Phase

0.0 miles

Learn More »

A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular Disease

This is a multi-center, randomized, double-blind, placebo-controlled, parallel-group study with an open-label extension. The study consists of 3 phases; screening phase (1 to 4 weeks), double-blind phase (24 weeks), and Open-label extension phase (24 weeks).

Phase

0.0 miles

Learn More »

Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

The trial is an open label extension study. Eligible patients from the RPC01-3101 trial diagnosed with moderate to severe ulcerative colitis will be enrolled to receive study medication for up to 5 years or until marketed approval.

Phase

0.45 miles

Learn More »

Effect of Rosuvastatin on Coronary Flow Reserve in Hypertensive Patients With Cardiovascular Risk

Statin therapy improves coronary flow reserve (CFR) and decreases cardiac morbidity and mortality in patients with coronary artery disease (CAD) and hypercholesterolemia via pleiotropic effects of statins, including regression of atheroma, stabilization of atherosclerotic plaques. Lipid lowering with a statin also provided beneficial effects in hypertensive patients with average levels ...

Phase

0.45 miles

Learn More »

Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B

This study evaluates the safety and immunogenicity of FP-02.2, a new therapeutic Hepatitis B vaccine, administered as an add-on therapy to entecavir or tenofovir. HBeAg-negative subjects will be randomized to receive low or high dose vaccine, in the presence or absence of IC31® adjuvant, or to receive placebo or IC31® ...

Phase

0.45 miles

Learn More »